Navellier & Associates’s ClearPoint Neuro CLPT Stock Holding History

Navellier & Associates’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$892K	Hold	50,000	–	–	0.07%	191
2026 Q1	$455K	Hold	50,000	–	–	0.05%	226
2025 Q4	$684K	Hold	50,000	–	–	0.08%	182
2025 Q3	$1.09M	Hold	50,000	–	–	0.11%	168
2025 Q2	$597K	Hold	50,000	–	–	0.07%	196
2025 Q1	$694K	Hold	50,000	–	–	0.1%	172
2024 Q4	$769K	Hold	50,000	–	–	0.09%	196
2024 Q3	$561K	Hold	50,000	–	–	0.08%	200
2024 Q2	$270K	Hold	50,000	–	–	0.03%	296
2024 Q1	$340K	Buy	+50,000	New	+$349K	0.04%	279

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Navellier & Associates's CLPT Position: Q2 2026 in Review

Navellier & Associates held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 50,000 shares worth $892K. The position accounts for 0.07% of the portfolio, ranked #191.

Navellier & Associates first reported a position in CLPT in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.09M in Q3 2025. 128 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Navellier & Associates held 50,000 shares of ClearPoint Neuro worth $892K as of Q2 2026.
Navellier & Associates left its ClearPoint Neuro share count unchanged in Q2 2026.
ClearPoint Neuro made up 0.07% of Navellier & Associates's portfolio in Q2 2026, its #191 holding.
Navellier & Associates first reported a position in ClearPoint Neuro in Q1 2024 and has held it in 10 quarters since.
Navellier & Associates's ClearPoint Neuro position peaked at $1.09M in Q3 2025.
128 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.